Financings Of The Fortnight: Secondary Offerings Up From Pace Set In 2010 And 2011
This article was originally published in The Pink Sheet Daily
Plus news on recent financings by Genkyotex, Synageva, Nektar Therapeutics and Edmond de Rothschild Investment Partners.
You may also be interested in...
Financings Of The Fortnight Notices Autumn Coincides With Increase In Option Deals
Plus news on recent financings by MyoKardia, Biogen Idec, Annovation and Wellington Partners.
Clinigen Raises $80 Mil. In Rare U.K. Flotation While Europe's Wellington Partners Raises $91 Mil. For New Life Sciences Fund
Hopes in Europe’s cash-strapped biotech sector were rekindled when specialty drug and contract services company Clinigen said it will be Britain’s first public pharma listing in five years and by investors from Europe, the U.S. and the Middle East piling into a new life sciences investment fund set up by pan-European VC firm Wellington Partners.
GenKyoTex, PsiOxus Raise VC Funding In Europe To Reach Phase II POC
GenKyoTex's first-in-class NOX inhibitors and PsiOxus's oncolytic viruses attract funding from European VCs to cross "death valley."